Natural vasopressins have been used, with varying success, in attempts to stop bleeding from esophageal varices for over two decades. Reasons for lack of success include (a) failure to induce a sufficiently prolonged and constant vasoconstrictor effect at the bleeding site, (b) dangerous side-effects, and (c) release of plasminogen activator induced by the peptides which can lyse any clot as it forms.
The spectrum of biological actions of VP is one of the widest of any known substance, from claims of memory consolidation and known hormone releasing actions in the CNS to contractile and permeability effects in all peripheral organs [2, 4] . At about the same time that VP was first being used in cases of bleeding into the gut lumen, it was also recognized as the most potent known "releaser" of plasminogen activator [9] -hardly an activity to be desired in a bleeding state. Because of the complexities of combinations of biologically advantageous and disadvantageous actions, along with limitations imposed by the short biochemical and response half-lives of the parent hormones, efforts haved been directed over the past decade to "reshuffle" their advantages and to prolong their actions by synthetic alteration of the natural cyclic nonapeptide. The present communication deals with some of the details of these efforts in terms of both mechanism of action and apparent clinical effects.
THE LONG-ACTING VP ANALOGS-TWO APPROACHES Two principles of prolonging the action of oligopeptide hormones have so far been used: (a) retardation of the degradative action of enzymes which inactivate the hormones, or (b) utilization of these and/ or similar enzymes in order to cleave inactive synthetic prohormones or hormonogensi thereby releasing the active hormone at a slow rate. We can illustrate this in the case of VP by indicating preferential sites of primary cleavage in the sequence formula of the molecule, which causes immediate inactivation: In order of probable quantitative significance, the inactivating cleavage sites are: (a) 1-2 C-N (aminopeptidase), (b) 8-9 C-N ("carboxamidopeptidase"), (c) 1-6 S-S (disulfide reductase), (d) 7-8 C-N ("post-Proline cleaving enzyme"), (e) 6-7 C-N ("pressinoicase"). Of these five sites, the first three would account for the vast majority of inactivated peptide since the first is present intracellularly in all tissues and the others are in liver and kidney, each of which has a very large blood flow [4] . The fifth site has so far been localized to the median eminence region of the midbrain [10] so that, while not quantitatively significant, it could still be functionally important if part of the VP molecule were acting in the midbrain in different areas than those associated with the parent hormone. Change in the biological spectrum of activity-in contrast to prolongation of action-generally involves the side-chains rather than the backbone of a bioactive peptide. The classical first approach to prolonging activity is prevention of aminopeptidase action by desamination of the N-terminus [11] : Lys (dLVP) CH2-CH2-CO-Tyr-Phe-Gln-Asn-Cys-Pro--Gly-NH2 CH2-CH2-CO-Tyr-Phe-Gln-Asn-Cys -Pro-D-Arg-Gly-NH2 (dDAVP) S S These properties have made dDAVP the drug of choice in the management of diabetes insipidus [28] and also of use in treating actual or potential bleeding episodes in hemophiliac patients and those with von Willebrand's disease [27] . Finally, site (c) can be stabilized by supplanting the S-S bridge by a thioether (SCH2 or CH2S) or an ethylene (CH2CH2) bridge (referred to here as monocarba and dicarba, respectively) [12] . A schematic representation of a monocarba analog of VP is shown below:
Except for the case of antidiuresis, where dCCAVP has both high potency and prolonged action, dicarba analogs have prolonged VP-like actions but low potency [12, 13] so that large doses would be required in therapeutic applications. The monocarba VP analogs (either at sequence position 1 or 6) however have not only a prolonged action, but their potency is higher than that of the parent hormone [14] . Physical chemical parameters related to conformation in solution do not reveal any alteration by monocarba substitution of the active stereochemical form of the parent molecule [13] .
The second principle for obtaining prolonged action is illustrated by the formula:
X-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 S S where X = N-terminal peptide chain extensions, the most useful of which is Gly-GlyGly [15] . Such hormonogens, including N-glycyl-glycyl-glycyl{8-lysine]-vasopressin (Glypressin = tGLVP) provide an inefficient approach to prolonging activity because during the time interval required for aminopeptidase "activation" by cleavage of the added N-terminal glycines, other enzymes inactivate by cleavage of the Cterminal tripeptide (and for this reason it is 8-Lys and not 8-Arg, since in the latter case inactivation would be even more rapid and efficient [4] [16] which allowed serial sampling of sufficient blood for parallel estimations of both plasma antidiuretic activity (rat assay) and "LVP" concentrations by RIA. The inverted commas about LVP refer to the fact that the Ab for LVP is sensitive to the C-terminal tripeptide, so that it cannot distinguish between tGLVP and LVP or even some fragment thereof. The time courses of both parameters suggested that tGLVP per se disappears from the circulation as rapidly (3-min half-life) as most other oligopeptide hormones, with a subsequent slow rise in both activities to peak at about 20 min. This was followed by a slow disappearance curve which was hard to quantitate. When release kinetics are estimated by biological action on the target organ, response durations vary greatly depending upon the organ and, in the case of the uterus, very much also on the stage of the estrus cycle. Thus, in man durations vary from 120 min on gut motility and facial blanching to over 8 h in the just premenstrual uterus after a single bolus dose of about 5 mcg/ kg. Since it seems highly unlikely that injected peptide would still be circulating 8 h after injection of a hormonogen, the suggestion has been made both for dDAVP and tGLVP that some sequestration may occur in a "receptor compartment" which protects the peptide from inactivating enzymes [12, 14] . [20] . The mortality of a large second or third bleed in a decompensated cirrhotic patient remains between 60 and 80o in various reports [21, 22] . Careful use of VP or correct placement of a Blakemore-Sengstaken tube improves results, but both procedures require great skill and experience for successful use, and these latter parameters are not available at all clinical establishments-which often results in long and dangerous transport of actively bleeding patients to specialized centers.
VP AND VP-ANALOG ACTIVITIES OF RELEVANCE TO GASTROENTEROLOGY
When one looks at the walls of the submucosal varix, particularly near the site of a hemorrhage, there appears to be little smooth muscle to respond to any VP stimulus by contraction. In fact, the suggestion has been made on the basis of X-ray and balloon studies of experimental cirrhosis in dogs and also in patients [23] that the VP effect is actually on the smooth muscle of the lower one-third of the esophageal wall. Theoretically, constriction of esophageal smooth muscle may shut off blood flow in the penetrating vessels connecting the para-esophageal coronary vein with the submucosal varices (Fig. 2) . If this mechanism is valid, it is clear that any pharmacological effect, to be useful, must be continuous for a sufficiently long period to allow the defect in the wall to seal, close off, and organize, and this long-acting activity must not involve an increase in plasma PA levels. A further mechanism of VP action in variceal bleeding is the documented [7] cavity, the decrease in portal venous pressure must result from a decreased arterial inflow into the bed drained by the portal vein (unless, in addition, the portal vein reacts differently to VP peptides than the other small and large veins in the visceral bed).
In a recently published preliminary series of heavy variceal bleeders, tGLVP therapy with a mean treatment duration of 5 days was associated with a 13% mortality, compared with 67% in the control group which received either no peptide drug or only intravenous Pitressin. The only other therapeutic measures used (Blakemore-Sengstaken intubation, blood replacement, frequent bacotracin enemas) were applied to both the treated (tGLVP) and control groups [7] . The acute effects of tGLVP have been observed directly by fiberoptic esophagoscopy and sequential color photographs in such patients and one case is so documented in Plate 1 (courtesy of Dr. A. Thiede, Christian-Albrechts-Universitaet, Kiel, FRG).
Clearly, in variceal bleeders as in peptic ulcer bleeders, more extensive clinical data are needed. We still do not know even in the small series already treated whether tGLVP changed the ultimate prognosis of these patients. Bleeding Peptic Ulcers, Both Gastric and Duodenal (24) In the first published series of patients to receive tGLVP, 9 of the 11 gut bleeders had peptic ulceration with acute onset of heavy bleeding starting from an otherwise compensated and "normal" baseline state. Most of the cases had X-ray proven diagnoses before the bleeding episode in question, and many had bled once previously but had not been subjected to gastric resection. The therapeutic approach was adapted to the trial-in order to try to evaluate the effect of tGLVP, the patients were treated only with blood replacement at a rate which allowed them to reach a balanced state (with respect to Hb and Hct levels) during 1-3 days of close observation in hospital with no other medication. These balanced states were established at quite low levels (e.g., about 8-9 g%s of Hb (Fig. 3) ) with an unchanged rate of transfusion which was then equated to the rate of blood loss from a hypovolemic patient. At this [24] . point tGLVP was administered at a dosage of 50 mcg/ kg/ day in divided doses every 6-8 h i.v., and blood replacement was either stopped or slowed-it was in no case continued at the same or a greater rate than before onset of drug therapy. No other drugs were used. In all patients in this small group, the onset of tGLVP therapy was associated with a rising curve of Hb, Hct, and rbc levels, as well as of arterial BP. Stool benzidine tests showed that bleeding had stopped within 2 days after the onset of tGLVP and all of the patients were discharged in good condition within one week. Under ordinary conditions, continuous heavy bleeding over 3-4 days would have been taken as indication for surgical intervention.
In addition to this therapeutic action, later experience has shown that tGLVP may be useful in rapid prognosis. It seems that the action of tGLVP is useful in treating blood loss from small vessels in shallow ulcers. If the gastro-duodenal artery has been eroded, no vasoconstrictor drug can stop the flow and a lack of response to tGLVP (given in as high a dosage as 3-4 mg q 6-8 h) has been considered as indication for prompt surgical intervention [26] .
Profuse Mucosal Bleeding from Gastritis Several cases of profuse GI bleeding from endoscopically verified, diffuse hemorrhagic gastritis have occurred in patients with no previous symptoms of peptic ulcer, but who were on high doses of aspirin, butazolidine, etc., for arthritic conditions. Their response to tGLVP appeared to be both marked and rapid. Bleeding stopped within 20 min as monitored by direct intragastric observation [24, 26] .
Control of Profuse Bleeding During Upper Abdominal
Surgery Related to Liver Cirrhosis While this application might eventually prove to be generally useful in abdominal surgery or trauma because of the prolonged arteriolar and venoconstrictor action of the drug, the action is most marked in portocaval and splenorenal shunt surgery. The presence of a profuse bed of collateral veins around the liver combined with portal venous hypertension often results in very profuse small vessel bleeding during the surgery which is hard to control. One mg i.v. doses of tGLVP have been reported to result in lessening or stopping of this bleeding within 5 min and these findings could be correlated with a decrease in portal venous pressure measured by direct venipuncture [7] . There was no evidence that this method of hemostasis was associated with any bleeding "rebound."
There is no experience as yet with the action of VP-analogs in bleeding from the lower bowel. The blood flow effects of the analogs on the gut in rats was measured in the entire gut at once and no differentiation was made between different parts. Since there is a clear clinical response to upper GI bleeding, we know that the pharmacological action involves the upper gut-only further experimental and clinical observation will determine whether the actions are equally valid on the lower bowel as well.
The only human experience with any carba modification of VP (1-desamino-6-monocarba-AVP) has involved healthy, non-pregnant women volunteers. In these studies of uterine blood flow and intraluminal pressure tGLVP was shown to be onetenth as potent as dCAVP in reducing endometrial and myometrial blood flow and increasing luminal pressure. tGLVP is an approved drug in some parts of Europe for the treatment of menorrhagia and metrorrhagia.
In conclusion, it would appear that structure-activity studies and synthetic alterations have been successful in reshuffling the broad spectrum of VP activities. For clinical application the problems have been: (1) to suppress some actions and leave others either untouched or augmented, and (2) to prolong the duration of action after single doses in a controlled manner. Of the two basic approaches presented-hormonogen and monocarba VP analogs-each has some advantages and some faults. In the present state of the art, monocarba analogs have the advantages of enhanced potency and prolonged action, whereas hormonogens combine prolongation of the most desirable actions of VP, suppression of undesirable actions on clotting and the myocardium with a high safety factor.
